Analytical Performance Specifications for Lipoprotein(a), Apolipoprotein B-100, and Apolipoprotein A-I Using the Biological Variation Model in the EuBIVAS Population

European Federation of Clinical Chemistry and Laboratory Medicine Working Group on Biological Variation, Noemie Clouet-Foraison, Santica M. Marcovina, Elena Guerra, Aasne K. Aarsand, Abdurrahman Coşkun, Jorge Diáz-Garzoa, Pilar Fernandez-Calle, Sverre Sandberg, Ferruccio Ceriotti, Anna Carobene

Research output: Contribution to journalArticle

Abstract

BACKGROUND: With increased interest in lipoprotein(a) (Lp[a]) concentration as a target for risk reduction and growing clinical evidence of its impact on cardiovascular disease (CVD) risk, rigorous analytical performance specifications (APS) and accuracy targets for Lp(a) are required. We investigated the biological variation (BV) of Lp(a), and 2 other major biomarkers of CVD, apolipoprotein A-I (apoA-I) and apolipoprotein B-100 (apoB), in the European Biological Variation Study population. METHOD: Serum samples were drawn from 91 healthy individuals for 10 consecutive weeks at 6 European laboratories and analyzed in duplicate on a Roche Cobas 8000 c702. Outlier, homogeneity, and trend analysis were performed, followed by CV-ANOVA to determine BV estimates and their 95% CIs. These estimates were used to calculate APS and reference change values. For Lp(a), BV estimates were determined on normalized concentration quintiles. RESULTS: Within-subject BV estimates were significantly different between sexes for Lp(a) and between women aged <50 and >50 years for apoA-I and apoB. Lp(a) APS was constant across concentration quintiles and, overall, lower than APS based on currently published data, whereas results were similar for apoA-I and apoB. CONCLUSION: Using a fully Biological Variation Data Critical Appraisal Checklist (BIVAC)-compliant protocol, our study data confirm BV estimates of Lp(a) listed in the European Federation of Clinical Chemistry and Laboratory Medicine database and reinforce concerns expressed in recent articles regarding the suitability of older APS recommendations for Lp(a) measurements. Given the heterogeneity of Lp(a), more BIVAC-compliant studies on large numbers of individuals of different ethnic groups would be desirable.

Original languageEnglish
Pages (from-to)727-736
Number of pages10
JournalClinical Chemistry
Volume66
Issue number5
DOIs
Publication statusPublished - 2020

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Biochemistry, medical

Fingerprint Dive into the research topics of 'Analytical Performance Specifications for Lipoprotein(a), Apolipoprotein B-100, and Apolipoprotein A-I Using the Biological Variation Model in the EuBIVAS Population'. Together they form a unique fingerprint.

  • Cite this

    European Federation of Clinical Chemistry and Laboratory Medicine Working Group on Biological Variation, Clouet-Foraison, N., Marcovina, S. M., Guerra, E., Aarsand, A. K., Coşkun, A., Diáz-Garzoa, J., Fernandez-Calle, P., Sandberg, S., Ceriotti, F., & Carobene, A. (2020). Analytical Performance Specifications for Lipoprotein(a), Apolipoprotein B-100, and Apolipoprotein A-I Using the Biological Variation Model in the EuBIVAS Population. Clinical Chemistry, 66(5), 727-736. https://doi.org/10.1093/clinchem/hvaa054